

Effect of Almond Consumption on Serum Lipid Profile in Dyslipidemic Adults

FARAH NAZ TAHIR¹, SYED IMRAN ALI SHAH², MUHAMMAD DANYAL³, JAVED ANVER QURESHI⁴

ABSTRACT

Aim: Cardiovascular disorders (CVDs) constitute a serious global health problem. Dyslipidemia is known to alter the risk of development of CVDs. Dyslipidemia may be associated with poor dietary habits and inclusion of nuts in diet has been shown to improve blood lipid levels. The present study evaluated the effect of almond intake on dyslipidemic subjects from the local population.

Methods: A prospective non-randomized study design was employed. Dyslipidemic individuals (n=21) with an age range from 21 to 60 years were recruited for the study. Baseline fasting blood samples were drawn from each subject and stored. Then subjects were asked to consume 50g/day almonds (without peel) for 30 days. On the 31st day, blood samples were again collected from each subject after an overnight fast. Both baseline and post-treatment serum samples were subjected to lipid profile analysis.

Results: Consumption of almonds significantly decreased the serum cholesterol, serum low-density lipoproteins (LDL) and serum triglyceride levels. Serum high-density lipoproteins (HDL) levels were increased but the increase was not statistically significant.

Conclusion: Almond intake was shown to beneficially alter key aspects of lipid profile of dyslipidemic individuals towards the desired values. Almonds may be used as a simple dietary strategy to prevent dyslipidemia and CVDs.

Keywords: Dyslipidemia, Cardiovascular disorders, Lipid Profile, Coronary Heart Disease

INTRODUCTION

Cardiovascular disorders (CVDs) including coronary heart disease (CHD) and stroke are considered a major health concern all over the world¹. There are several factors that trigger the development of CVDs such as sedentary lifestyle, smoking, excessive alcohol consumption, obesity, poor dietary habits and other co-morbidities. These risk factors negatively modify the metabolic milieu and lead to CVDs².

Dyslipidemia is a common adverse metabolic change that contributes to the development of CVDs. It is defined as an elevated level of total cholesterol or low-density lipoprotein (LDL) or a decreased level of high-density lipoprotein (HDL) or both. In the United States, more than one-quarter of adults are dyslipidemic or are taking lipid-lowering medication³. Patients with CVDs receive pharmacotherapy with statins and are advised lifestyle modifications like increased physical activity, cessation of smoking and dietary changes as secondary prevention measures to protect against recurrent cardiac events and all-cause mortality².

The American Heart Association (AHA) recommends a diet rich in nuts, fruits and vegetables and low in saturated fats for both primary and secondary prevention of CVDs⁴. Nut intake (such as pistachios, peanuts, walnuts, almonds) causes improvements in serum levels of total cholesterol, triglycerides, and LDL, thereby reducing the risk of CVDs^{5,6,7,8}.

Almonds (*Prunus dulcis*) contain a high amount of monounsaturated fat, α -tocopherol, fiber, minerals (copper, magnesium) and phytochemicals including phytosterols and polyphenols. This nutrient distribution in almonds is associated with a decrease in the risk of CVDs among those individuals who consume them on a regular basis⁹. Epidemiological studies have shown that almonds have positive effect on body weight, serum cholesterol, blood glucose, inflammation and oxidative stress¹⁰. To our knowledge, no adequately designed study has been conducted in the local population to observe effect of almond intake on lipid profile in dyslipidemic individuals. The present study was aimed at determining the potential positive impact of almond consumption on the lipid profile of dyslipidemic patients.

MATERIALS AND METHODS

A prospective non-randomized within subject study design was used. The study was carried out at IMBB, UOL in collaboration with Jinnah hospital Lahore, Akram Hospital and Central Park Medical College, Lahore. The study was conducted between April to September 2016. The study was approved by Ethical Committee, Institute of Molecular Biology and Biochemistry (IMBB), University of Lahore (UOL). A total of 21 participants were recruited for the study based on the predefined eligibility criteria. Written informed consent was obtained from each participant after providing detailed information about the study. Male and female individuals having serum total cholesterol > 200mg/dl, serum HDL < 40mg/dl, serum LDL > 130mg/dl, serum fasting triglycerides > 150mg/dl were included for the study. Individuals with hypertension, diabetes mellitus, hypersensitivity to almonds, peptic ulcer, kidney disease, CVD, malignancy, urinary tract infections or taking lipid-lowering medications were excluded from the study. Pregnant females were also excluded.

¹Institute of Molecular Biology and Biotechnology, University of Lahore, Department of Biochemistry, Central Park Medical College, Lahore Pakistan

²Dept of Biochemistry, Central Park Medical College, Lahore

³4th year MBBS student, Central Park Medical College, Lahore,

⁴Institute of Molecular Biology & Biotechnology, University of Lahore

Correspondence to Dr. Syed Imran Ali Shah, Associate Professor and Head, Email: s.shah10@alumni.imperial.ac.uk Cell: 03371429596

After recruitment, instructions were given to each subject about the dose and intake of almonds (50 grams per day). American almonds packaged in plastic bags weighing 50 grams each were given to each subject. Subjects were advised to take one packet of almonds everyday (for a dose of 50grams/day) before breakfast. Lipid lowering medicines were stopped for individuals taking them. Other potential lipid lowering ingredients like garlic, ginger etc. were also stopped for the period of one month. The subjects were asked to continue with their usual diet and physical activity.

Blood samples were collected at two separate time-points; once at baseline i.e. before starting on almonds and then on the 31st day after the start of almond intake. For blood sample collection, the subjects were advised not to eat or drink anything except water for a period of 12 hours before sample collection. 5ml blood was obtained through sterile venipuncture in a vacutainer tube not containing any anticoagulant. Samples were incubated at room temperature for 30-40 minutes in upright position. The tubes were then centrifuged for 15 minutes at 2000 RFC. The supernatant containing serum was collected in a clean tube and stored at 4 C. Lipid profile assays were performed for serum cholesterol, LDL, HDL, VLDL and triglycerides using commercially available kits.

Sample size was calculated by keeping the power of study at 90% and level of significance at less than 5%. Descriptive data were presented as percentages and frequencies. Mean + SEM was calculated for quantitative variables. Paired sample T-test was performed to observe

group mean differences. P-values <0.05 were considered significant.

RESULTS

The age range of the study subjects (n=21) was 21-60 years. Of the 21 subjects, 9 were females (42.85%) and 12 were males (57.14). 5 (23.8%) of the 21 subjects had a family history of diabetes mellitus. Mean serum cholesterol level before treatment was 242.29 mg/dl with a range of 201-368mg/dl. Mean serum cholesterol after treatment was 196.67 mg/dl with a range of 148-290 mg/dl. Serum cholesterol was significantly decreased after treatment (p<0.001) (Table 1). Mean serum LDL before treatment was 153.24 mg/dl with a range of 78-199 mg/dl. Mean serum LDL after treatment was 129.10 mg/dl with a range of 76-160 mg/dl. Serum LDL was significantly decreased after treatment (p<0.001) (Table 1). Mean serum HDL level before treatment was 41.90 mg/dl with a range of 31-60 mg/dl. Mean serum HDL after treatment was 42.42 mg/dl with a range of 26-61 mg/dl. The increase in mean serum HDL was not statistically significant (p=0.932) (Table 1). Mean serum triglycerides level before treatment was 179.33 mg/dl with a range of 127-398-127 mg/dl. Mean serum triglycerides after treatment was 175.38 mg/dl with a range of 72-381 mg/dl. Serum triglycerides was significantly decreased after treatment (p<0.001) (Table 1). Mean serum VLDL level before treatment was 36.19 mg/dl with a range of 22-79 mg/dl. Mean serum VLDL after treatment was 28.71 mg/dl with a range of 14-62 mg/dl. The decrease in mean serum VLDL after treatment was not statistically significant (p=0.695) (Table 1).

Table 1: Difference in serum lipid profile before and after treatment with almonds

Parameters	Mean Serum Level±SEM (n=21)		Mean Difference	Trend	p-value
	Before Treatment	After Treatment			
Cholesterol	242.29	196.67	45.62	↓	0.000*
LDL	153.24	129.10	24.14	↓	0.002*
HDL	41.90	42.42	- 0.24	↑	0.932
Triglycerides	179.33	175.38	3.95	↓	0.002*
VLDL	36.19	28.71	7.48	↓	0.695

*Difference is significant at p < 0.05

Table 2: Therapeutic efficacy of almonds in dyslipidemic subjects

Lipid Profile Range	Before	After
Desirable	0	11
Borderline	9	07
High risk	12	3

The base line lipid profile indicated that out of the 21 dyslipidemic subjects, 12 subjects were high risk whereas 9 subjects were in the border line range. After treatment with almonds, 11 out of the 21 subjects had normal lipid profile while 7 were in the border line range. Only 3 subjects had high risk dyslipidemia (Table 2).

DISCUSSION

Dyslipidemia is a metabolic disorder which predisposes affected individuals to CVDs and is associated with increased morbidity and mortality³. The aim of current study was to evaluate the effects of almonds in dyslipidemic patients. The results from the present study indicated that the consumption of almonds by dyslipidemic subjects led to

a favorable lipid profile with a significant decrease in the serum cholesterol, serum LDL levels and serum triglycerides levels (Table 1). Regular intake of 50 grams of almonds every day for one month brought the lipid profile of 52% of the dyslipidemic subjects into the desirable range without any concomitant pharmacological therapy (Table 2). It has been shown previously that the intake of almonds 4 times in a week decreased the risk of CVDs by 38% as compared to non-consumers⁴. Almonds have been shown to reduce LDL levels by upto 10% with a consequent 2% decline in the risk of CVDs has been documented^{11,12,13}.

Daily consumption of almonds in the range of 25 to 168 g per day has been shown to decrease the serum cholesterol levels. In a recent study on rats, almonds were shown to improve HDL levels and normalize total cholesterol and LDL levels by inhibiting de novo cholesterol synthesis¹⁴. Almond intake has also been associated with a favourable fatty acid profile¹⁵. Almond consumption has been shown to improve alpha-tocopherol levels in patients with CHD¹⁶. The phytosterols, fiber, and alpha-tocopherol in almonds are suppress cholesterol absorption and increase

its excretion⁽⁸⁾. Mechanisms responsible for the LDL reduction observed with almonds include decreased reabsorption of cholesterol and bile acids, increased excretion of cholesterol and bile acids and increased in the LDL receptor activity. Almonds also regulate de novo cholesterol synthesis and bile acid production¹⁴. The fibers present in almonds are also known to decrease oxidative stress, increased serum tocopherol and decrease lipid peroxidation (17, 18). Nuts are recognized as heart-healthy foods but there is a fear of weight gain with intake of nuts. Several studies have looked at the changes in weight and BMI with almonds intake but most of them reported no adverse effect in terms of weight gain^{17,19,20,21}. Serum triglyceride levels are known to show short-term fluctuations in response to the type of food ingested. Our study showed a decrease in serum triglycerides following almond therapy. Previous studies have yielded mixed results in this regard but most of these studies were conducted in animal models or individuals with a normal lipid profile²².

CONCLUSION

Regular almond intake has a beneficial impact on serum lipid profile in dyslipidemic patients which in turn can potentially reduce their risk of developing CVDs. Future research with larger sample sizes and prospective randomized controlled study designs need to be conducted to evaluate the effect of almond intake on the incidence of CVDs. The results from such studies may further highlight health benefits of almonds.

REFERENCES

- Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. *J Am Coll Cardiol*. 2017;70(1):1-25.
- Stewart J, Manmathan G, Wilkinson P. Primary prevention of cardiovascular disease: A review of contemporary guidance and literature. *JRSM Cardiovasc Dis*. 2017;6:2048004016687211.
- Jeong JS, Kwon HS. Prevalence and clinical characteristics of dyslipidemia in Koreans. *Endocrinol Metab*. 2017;32(1):30-5.
- Albert CM, Gaziano JM, Willett WC, Manson JE. Nut consumption and decreased risk of sudden cardiac death in the Physicians Health Study. *Arch Gen Intern Med*. 2002;162:1382-7.
- Askin N, Aksoy N, Aksoy M, Bagci C, Gergerlioglu HS. Pistachio intake increases high-density lipoprotein levels and inhibits low-density lipoprotein oxidation in rats. *Tohoku J Exp Med*. 2007;212:43-8.
- Emekli-Alturfan E, Kasikci E, Yarat A. Peanuts improve blood glutathione, HDL-cholesterol level and change tissue factor activity in rats fed a high-cholesterol diet. *Eur J Clin Nutr*. 2007;46:476-82.
- Sambaiah., Fraser GE, Burke K, Knutsen SF, Hannelore B, Kristian DL. Effects of walnuts on serum lipid levels and blood pressure in normal men. *N Engl J Med*. 1991;328:603-7.
- Jambazian PR, Haddad E, Rajaram S, Tanzman J, Sabate J. Almonds in the diet simultaneously improve plasma alpha-tocopherol concentrations and reduce plasma lipids. *J Am Diet Assoc*. 2005;105:449-54.
- Kalita S, Khandelwal S, Madan J, Pandya H, Sesikeran B, Krishnaswamy K. Almonds and cardiovascular health: A review. *Nutrients*. 2018;10(4):1-10.
- Jaceldo-Siegl K, Sabaté J, Rajaram S, Fraser GE. Long-term almond supplementation without advice on food replacement induces favorable nutrient modifications to the habitual diets of free-living individuals. *Br J Nutr*. 2011;92:533-40.
- Sathe SK, Seeram NP, Kshirsagr HH. Fatty acid composition of California-grown almond. *J Food Sci*. 2008;73:C607-C14
- Jenkins PW, Kendall CW, Marchie A, Parker TL, Connelly PW, Qian W, et al. Dose response of almonds on coronary heart disease risk factors: blood lipids, oxidized low-density lipoproteins, lipoprotein (a), homocysteine, and pulmonary nitric oxide: a randomized, controlled, crossover trial. *Circulation* 2002;106:1327-32.
- Spiller GA, A. M, Olivera K, Reynolds J, Miller B, Morse SJ, et al. Effect of plant based diets high in raw or roasted almonds, or roasted almond butter on serum lipoproteins in humans. *J Am Coll Nutr*. 2003;22:195-200.
- Jamshed H, Gilani AH. Almonds inhibit dyslipidemia and vascular dysfunction in rats through multiple pathways. *J Nutr*. 2014;144(11):1768-74.
- Nishi S, Kendall CW, Gascoyne AM, Bazinet RP, Bashyam B, Lapsley KG, et al. Effect of almond consumption on the serum fatty acid profile: a dose-response study. *Br J Nutr*. 2014;112(7):1137-46.
- Chen CY, Holbrook M, Duess MA, Dohadwala MM, Hamburg NM, Asztalos BF, et al. Effect of almond consumption on vascular function in patients with coronary artery disease: a randomized, controlled, cross-over trial. *Nutr J*. 2015;14:61.
- Wien MA, Sabaté JM, D.N. I, Cole SE, Kandeel FR. Almonds vs complex carbohydrates in a weight reduction program. *Int J Obes*. 2003;27:1365-72.
- Zern TL, Fernandez ML. Cardioprotective effects of dietary polyphenols. *J Nutr* 2005;135:2291-4.
- Bes-Rastrollo M, Wedick NM, Martinez-Gonzalez MA, Li TY, Sampson L. Prospective study of nut consumption, long-term weight change, and obesity risk in women. *Am J Clin Nutr*. 2009;89:1913-9.
- Mattes RD, Kris-Etherton PM, Foster GD. Impact of peanuts and tree nuts on body weight and healthy weight loss in adults. *Am J Clin Nutr*. 2008;138:1741S-5S.
- Fraser GE, Bennett HW, Jaceldo KB, Sabate J. Effect on body weight of a free 76 kilojoule (320 calorie) daily supplement of almonds for six months. *J Am Coll Nutr*. 2002;21:275-83.
- Sheridan MJ, Cooper JN, Erario M, Cheifetz C. Pistachio nut consumption and serum lipid levels. *J Nutr Health*. 2007;135:2028-9.